Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01110733 · ClinicalTrials.gov registry record

Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry

A clinical trial, sponsored by Acrotech Biopharma.

Completed
Registry status
3,000
Enrollment target

NCT01110733: Completed study, sponsored by Acrotech Biopharma.

NCT01110733 is a clinical trial that has completed, run by Acrotech Biopharma. The registered enrollment target is 3,000 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01110733 has completed, sponsored by Acrotech Biopharma.

COMPLETED
Registry status
3,000 participants
Enrollment target

Study Summary

Prospective, longitudinal, multinational, observational study that will collect data on how patients with peripheral T-cell lymphoma (PTCL) are treated in academic and community practices.

Trial Details

FieldValue
Enrollment Target 3,000 participants
Start Date 2010-02
Est. Completion 2019-12
Acrotech Biopharma

24 total trials

What the finished NCT01110733 record still lists

NCT01110733 is an observational study that tracks outcomes without assigning an intervention. Its 3,000 participants enrollment target places it among the larger protocols in the corpus.

The record links to 0 conditions, and to 0 interventions.

NCT01110733 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01110733 about?

NCT01110733 is a clinical study titled "Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry". Prospective, longitudinal, multinational, observational study that will collect data on how patients with peripheral T-cell lymphoma (PTCL) are treated in academic and community practices.

What is the current status of trial NCT01110733?

This trial is currently completed. The enrollment target is 3,000 participants. The study started on 2010-02. Estimated completion is 2019-12.

Who is sponsoring clinical trial NCT01110733?

This trial is sponsored by Acrotech Biopharma, which has 24 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00004847 · 3,000 participants · Phase 1

    Diagnosis of Pheochromocytoma

  • NCT00478712 · 3,000 participants

    Hirschsprung Disease Genetic Study

  • NCT00579566 · 3,000 participants

    Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma

  • NCT00816114 · 3,000 participants

    Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01110733, the US trial registry maintained by the National Library of Medicine. NCT01110733 (large enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.